Tumor Necrosis Factor- α Inhibits Albumin Gene Expression in a Murine Model of Cachexia

D. A. Brenner, M. Buck, S. P. Feitelberg, and M. Chojkier

Department of Medicine, University of California and Veterans Administration Medical Center, San Diego, California 92093

Abstract

The mechanisms responsible for decreased serum albumin levels in patients with cachexia-associated infection, inflammation, and cancer are unknown. Since tumor necrosis factor- α (TNF α) is elevated in cachexia-associated diseases, and chronic administration of TNF α induces cachexia in animal models, we assessed the regulation of albumin gene expression by TNF α in vivo. In this animal model of cachexia, Chinese hamster ovary cells transfected with the functional gene for human TNF α were inoculated into nude mice (TNF α mice). TNF α mice became cachectic and manifested decreased serum albumin levels, albumin synthesis, and albumin mRNA levels. However, even before the TNF α mice lost weight, their albumin mRNA steady-state levels were decreased $\approx 90\%$, and in situ hybridization revealed a low level of albumin gene expression throughout the hepatic lobule. The mRNA levels of several other genes were unchanged. Hepatic nuclei from TNF α mice before the onset of weight loss were markedly less active in transcribing the albumin gene than hepatic nuclei from control mice. Therefore, TNF α selectively inhibits the genetic expression of albumin in this model before weight loss. (*J. Clin. Invest.* 1990; 85:248–255.) albumin • cachexia • liver tumor necrosis factor- α , transcription

Introduction

Serum albumin levels are decreased in patients with cachexia-associated infection, inflammation, and cancer, and the reduction in serum albumin levels is used clinically as an indicator of the severity of the chronic disease state (1). Serum albumin levels reflect a complex interaction between the synthesis, volume of distribution, degradation, and losses of this protein. The mechanisms responsible for the hypoalbuminemia of cachexia are unknown. It has been shown that the hypoalbuminemia of chronic inflammatory diseases (2) and of chronic renal failure (3) is at least in part the result of decreased albumin synthesis. If albumin synthesis is decreased in cachexia, then this could be either a nonspecific effect of malnutrition or the specific effect of a humoral factor inhibiting albumin synthesis.

Tumor necrosis factor- α (TNF α),¹ a product of monocytes/macrophages, has been incriminated in the pathogenesis

of cachexia (4, 5). The administration of TNF α induces cachexia in animals (6, 7) as well as a negative nitrogen balance in patients (8). In addition, serum levels of TNF α are elevated in some patients with cachexia-associated chronic diseases including cancer (9), parasitic infections (4), and the acquired immunodeficiency syndrome (10). TNF α is a potent modulator of protein synthesis, and many of the severe metabolic abnormalities found in cachexia have been attributed to the effects of TNF α (4, 5). The question of whether TNF α inhibits albumin synthesis in vivo independent of malnutrition and weight loss remains to be determined. Therefore, we evaluated the regulation of albumin gene expression in a murine model of cachexia induced by chronically elevated levels of serum TNF α . We found that TNF α inhibits albumin synthesis at the transcriptional level even before the onset of weight loss.

Methods

Materials

[α -³²P] 2'-Deoxycytidine 5'-triphosphate and [α -³²P]uridine 5'-triphosphate were from ICN Immunobiologicals (Irvine, CA); [³⁵S] cytidine 5'-triphosphate (1,320 Ci/mmol) was from New England Nuclear (Boston, MA); ribonucleotides, deoxyribonucleotides, Klenow fragment of DNA polymerase I, RNase-free bovine serum albumin, dextran sulfate, and ribonuclease A were from Pharmacia LKB Biotechnology, Inc. (Piscataway, NJ); agarose, DNase I, RNase TI, and restriction endonucleases were from Bethesda Research Laboratories (Gaithersburg, MD); low melting point agarose and fast green were from Bio-Rad Laboratories (Richmond, CA); guanidine isothiocyanate was from International Biotechnologies, Inc. (New Haven, CT); Biotransfer membrane was from Pall Corp. (Glen Cove, NY); nitrocellulose membrane was from Schleicher & Schuell (Keene, NH); 4-morpholinepropanesulfonic acid (MOPS), guanidine HCl, antifoam emulsion, N-lauroyl sarcosine, lauroyl sulfate sodium salt, albumin reagent (BCG) and crystal violet were from Sigma Chemical Co. (St. Louis, MO); formamide was from EM Scientific (Gibbstown, NJ); formaldehyde solution was from Mallinckrodt Chemical Co. (Paris, KY); protease K, 1,4-piperazinediethanesulfonic acid (PIPES), and Sephadex G-50 prespun columns were from Boehringer-Mannheim (Indianapolis, IN); agar, tryptone, yeast extract were from Difco Laboratories (Detroit, MI); embedding medium (OCT compound) was from ICN Immunobiologicals; rabbit anti-mouse albumin antibody was from Cappel Laboratories (Malvern, PA); biotinylated goat anti-rabbit IgG and the alkaline-phosphatase system were from Vector Laboratories (Burlingame, CA); the monoclonal TNF α immunoassay was from Endogen (Boston, MA); recombinant human TNF α was from AmGen Biologicals (Thousand Oaks, CA); and nude mice were from Simonsen (Gilroy, CA) and Harlan Sprague Dawley (Indianapolis, IN).

Mouse model of cachexia. Chinese hamster ovary cells transfected with either the TNF α gene cloned into a mammalian expression vector (TNF α cells) or with the mammalian expression vector alone (CHO cells, control) were kindly provided by Dr. Oliff (Merk Sharp & Dohme Research Laboratories, West Point, PA) (6). Cells were grown in Dulbecco's modified essential medium supplemented with 10% fetal calf serum, penicillin (50 U/ml) and streptomycin (50 μ g/ml). The TNF α cells but not the CHO cells produced TNF α as measured by a

Address reprint requests to Dr. Brenner, Division of Gastroenterology, Department of Medicine, M-023-D, University of California, San Diego, La Jolla, CA 92093.

Received for publication 28 March 1989 and in revised form 5 September 1989.

1. Abbreviations used in this paper: MOPS, 4-morpholinepropanesulfonic acid; PIPES, 1,4-piperazinediethanesulfonic acid; TNF α , tumor necrosis factor- α .

The Journal of Clinical Investigation, Inc.
Volume 85, January 1990, 248–255

cytolytic assay. 4-wk-old nude mice were injected intramuscularly with either 10^7 CHO cells or 10^7 TNF α cells. Nude mice were housed in a temperature and humidity controlled facility. Animals had free access to food and water and they were killed at 14–21 d (before the onset of weight loss of the TNF α mice) and at 28–35 d postinoculation (after the onset of weight loss). TNF α cells at later passages markedly decrease their production of TNF α (6). When animals were inoculated with these TNF α cells they developed cachexia at ~ 10 wk.

TNF α levels were measured by a biological cytolytic assay, using a modification of the method of Armstrong et al. (11). L929 cells (kindly provided by G. Granger, University of California, Irvine) were plated at 3×10^4 cells per well in 0.1 ml of Eagle's minimal essential media containing 5% fetal calf serum, 2 mM glutamine, and 0.5 μ g/ml mitomycin in 96-well tissue culture plates. These plates were incubated at 37°C in 95% air/5% CO $_2$ for 24 h. Serial dilutions of TNF α samples and standards in media were added to the wells. The plates were incubated for an additional 48 h, drained of media, fixed with methanol, stained with 0.2% crystal violet for 30 min, solubilized with 10% methanol, and the absorbance at 540 nm was measured using a Biotech EL310 plate reader. Results were expressed in units of activity (1 μ = ~ 20 pg). In addition, serum TNF α were determined by an immunoassay using monoclonal antibodies against TNF α , according to the manufacturer's protocol.

Serum albumin concentrations. Serum albumin concentrations were determined by reacting serum or mouse albumin standards with bromocresol green, pH 4.2, at 25°C for 1 min and measuring absorbance at 628 nm (12).

Immunohistochemical staining. At 14–21 d and 28–35 d postinoculation with CHO or TNF α cells, mice livers were fixed in situ by perfusion with 4% paraformaldehyde in PBS via the aorta. The livers were sliced into 3-mm thick sections, postfixed for 2 h at 4°C in the same paraformaldehyde solution. The livers were washed in cold PBS for 10 min, cryoprotected in 30% sucrose PBS for 4 h and embedded and frozen in OCT compound at -70°C . 8- μ m cryostat sections were obtained and placed onto slides that had been pretreated with a solution of 100 μ g/ml of poly-L-lysine in 10 mM Tris, pH 8.0. Rabbit anti-mouse albumin was purified by affinity chromatography on a Reactigel 6 $\times$ (Pierce Chemical Co., Rockford, IL) column coupled to mouse albumin according to the manufacturer's procedure. The affinity purified rabbit anti-mouse albumin was used as the primary antibody in conjunction with biotinylated goat anti-rabbit IgG and the ABC-alkaline phosphatase system essentially as recommended by the manufacturer. Blocking was performed with gelatin instead of with serum. Nonspecific alkaline phosphatase reactions were blocked with levamisole and nonspecific antibody reactions assessed by omitting the first antibody. Fast green was used to counterstain the tissue sections.

Northern blotting. Total RNA from individual mouse livers was extracted in guanidine thiocyanate and pelleted by centrifugation of the extract through a cesium chloride cushion. Poly A+ RNA was purified by oligo dT cellulose chromatography. The plasmid pmalb2 (for albumin), pK α 1 (for α tubulin), and pMLC3-1 (complement component C3), and pa2M (α 2 macroglobulin) were kindly provided by S. Tilgham (13), N. Cowan (14), and G. Fey (15, 16), respectively. The cDNA inserts were purified and radiolabeled with [α - ^{32}P] dCTP using the random primer synthesis method (17). 2 μ g of poly A+ RNA per lane were electrophoresed in a 1% agarose gel. The gels were transferred to nylon filters and Northern blots were performed as described previously (18). The autoradiograms were quantitated by scanning with a laser densitometer interfaced with an integrator.

In situ hybridization. In situ hybridization was performed by a modification of published methods (19, 20). The albumin cDNA insert of the plasmid palb2 was subcloned into the SP6, T7 transcription vector pGEM blue 3 (Promega Biotec, Madison, WI). Antisense cRNA (complementary to the albumin messenger RNA) and sense RNA probes were generated from the same plasmid using [^{32}S]CTP without additional cold CTP. The radiolabeling reaction was performed according to the manufacturer's protocol with 0.075 nM CTP in a 5- μ l reaction volume. The radiolabeled cRNA probe was precipitated with

50 μ g of yeast tRNA and then resuspended in 80 μ l of 10 mM DTT. The probe was reduced in size by alkaline hydrolysis, ethanol precipitated, and then resuspended in 10 mM DTT 50% formamide.

The cryostat sections described above were postfixed in 4% paraformaldehyde in PBS for 5 min, washed in PBS, and dehydrated through graded ethanol. The sections were rehydrated and deproteinized with protease K 10 μ g/ml, 100 mM Tris, pH 8.0, 50 mM EDTA for 20 min. The slides were rinsed in water and then acetylated in 0.25% (vol/vol) acetic anhydride, 0.1 M triethanolamine, pH 8.0 for 10 min. The slides were then washed in 2 $\times$ SSC for 4 min, dehydrated, and air dried. The hybridization solution consisted of 50% formamide, 300 mM NaCl, 10 mM Tris, pH 7.5, 1 mM EDTA, 100 mM DTT, 5 $\times$ Denhart's solution, 1 mg/ml yeast tRNA, and 10% dextran sulfate. The [^{32}S]CTP-labeled RNA probe was added to the hybridization solution to give a final concentration of 5×10^5 cpm/slide. The hybridization solution was heated for 3 min at 65°C and then 20 μ l was added to each slide. A coverslip was applied and sealed with glue. Hybridization was carried out in a humidity chamber at 50°C for 18 h. The coverslips were removed and the slide washed four times in SSC and then incubated in 20 μ g/ml RNase and 10 U/ml RNase T1 in 0.5 M NaCl, 10 mM Tris, pH 8.0, 1 mM EDTA at 37°C for 1 h. The slides were then washed in descending concentrations of SSC containing 1 mM DTT with the most stringent washing being at 55°C in 0.1 $\times$ SSC. The slides were dehydrated in graded ethanol containing 0.3 M ammonium acetate. After air drying, the slides were dipped in a Kodak NTB2 emulsion containing 0.33 M ammonium acetate. The slides were exposed for 5 d at -20°C , and then developed. The sections were counterstained with hematoxylin and photographed using an IGS filter cube (Nikon).

Nuclear runoff transcription assay. Mouse liver nuclei were prepared by a modification of the procedure of Gorski et al. (21). Livers from two mice were combined and homogenized in 2.4 M sucrose 4:1 (vol of sucrose solution/weight of liver) in a glass Dounce homogenizer with a loose-fitting pestle. The homogenized liver was placed above a cushion consisting of 2.0 M sucrose, 10% glycerol. The nuclei were pelleted by a 130,000 g centrifugation at 0°C for 1 h in an SW28 rotor. They were resuspended in the transcription runoff assay buffer, washed once, and then resuspended again in this buffer. Nuclei were frozen at -70°C . The nuclear runoff transcription assay that was developed by Groudine et al. (22) and adapted by Wang and Calame (23) was used as previously described (18). After filters containing the denatured cDNA probes were hybridized with the radiolabeled RNA and washed repeatedly, the radioactivity was determined by liquid scintillation spectroscopy for individual cDNAs. Separate filters containing denatured plasmid pGEM blue 3 were used as negative controls. The transcriptional rate is expressed as the radioactivity incorporated into a specific mRNA that is detected by its hybridization to the denatured cDNA.

Results

2 wk after their inoculation with TNF α cells, mice had serum TNF α concentrations as measured by a biological assay comparable to those reported previously (6). Serum TNF α levels remained elevated in TNF α mice at 4–5 wk after inoculation (Table I). The presence of circulating human TNF α was confirmed with a specific immunoassay utilizing monoclonal anti-human TNF α antibodies (Table I). TNF α was never detected in CHO mice (Table I). The TNF α and CHO mice maintained identical weights for about the first 2–3 wk after inoculation. The TNF α mice then began to progressively lose weight, whereas the CHO mice did not. As previously reported (6), TNF α mice at 4–5 wk after inoculation manifested severe weight loss (Fig. 1). The cachectic TNF α mice had significantly decreased serum albumin levels compared to the CHO control mice (Table II).

Table I. Serum TNF α Levels in TNF α Mice

Experimental conditions*	Serum TNF α (ng/ml)	
	L929 assay [‡]	ELISA [‡]
TNF α mice (before onset of weight loss)	0.08 $\pm$ 0.003	0.3 $\pm$ 0.1
TNF α mice (after onset of weight loss)	48 $\pm$ 0.5	1.5 $\pm$ 0.4
CHO mice	ND	ND

* Nude mice were inoculated with either TNF α -cells (TNF α -mice) or CHO cells (CHO-mice) as described in Methods.

[‡] Serum TNF α levels were determined by a biological assay (L929) and by an immunoassay (ELISA) as described in Methods. Values are mean $\pm$ SEM of at least triplicate samples. ND, none detected.

Livers from cachectic TNF α and CHO mice were perfused in situ and used for immunohistochemical studies. In the CHO mice, albumin was detected in high abundance diffusely through the hepatic lobule. On the other hand, in the cachectic TNF α mice, the abundance of albumin was greatly depressed (Fig. 2). As controls, sections were incubated in the absence of first antibody, which did not demonstrate any specific staining, or with antimurine Ig as the first antibody, which did not demonstrate any hepatocyte specific staining (data not shown). Northern blot analysis revealed a marked decrease in the steady state levels of albumin mRNA but not of β -actin mRNA in the cachectic TNF α mice compared with the CHO mice (Fig. 3 A). The decrease in hepatic albumin protein and mRNA levels in this model of cachexia is comparable to other models of weight loss reported previously by us (24) and others (25, 26).

If TNF α modulates albumin gene expression independently of its effects of malnutrition and weight loss, we would expect TNF α to decrease albumin production before the onset of weight loss. Before the onset of weight loss, TNF α mice had significantly decreased serum albumin levels compared to age-matched CHO control mice (Table II). In addition, immunohistochemically detected albumin was decreased in the hepatocytes of TNF α mice before weight loss (data not shown).

In order to investigate the mechanism by which TNF α inhibits albumin production, expression of the albumin gene was assessed by measuring steady state mRNA levels, cellular localization, and transcriptional activity. Hepatic albumin mRNA content was measured in 10 precachectic TNF α mice and 10 age-matched CHO mice, and a representative Northern

Figure 1. Change in weight of CHO and TNF α mice postinoculation of CHO or TNF α cells. CHO or TNF α cells (10^7) were inoculated into age-matched male nude mice. Each point represents the mean weight change $\pm$ SEM of at least four mice.

Table II. Serum Albumin Levels in CHO and TNF α Mice

Experimental conditions*	Serum albumin [‡] g/dl
Experiment I: Precachectic TNF α mice	
CHO mice, 2 wk ($n = 5$)	1.9 $\pm$ 0.1
TNF α mice, 2 wk ($n = 6$)	1.7 $\pm$ 0.1
Experiment II: Cachectic TNF α mice	
CHO mice, 4 wk ($n = 4$)	2.7 $\pm$ 0.2
TNF α mice, 4 wk ($n = 5$)	2.1 $\pm$ 0.1
TNF α mice, 10 wk ($n = 4$)	1.7 $\pm$ 0.1

* Nude mice were inoculated with either CHO cells (CHO-mice) or TNF α cells (TNF α -mice) as described in Methods. The number of weeks designates the time postinoculation of cells.

[‡] Determined as described in Methods. $P < 0.05$ for TNF α mice, 2 wk, $P < 0.01$ for TNF α -mice, 4 wk and $P < 0.001$ for TNF α -mice, 10 wk.

blot is shown in Fig. 3 B. The albumin mRNA levels of the CHO mice were 100 ± 10.3 (mean $\pm$ SEM in relative densitometry units) and of the TNF α mice were 13.3 ± 3.8 ($P < 0.005$). Additional analysis of hepatic mRNA revealed no changes in β -actin, complement C3, or α -tubulin levels in the TNF α mice (Fig. 3 B).

To assess the expression of the albumin gene throughout the hepatic lobules, we performed in situ hybridization using a ³⁵S-albumin antisense cRNA probe. In the CHO mice, abundant albumin mRNA was detected in the liver by in situ hybridization (Fig. 4 A). As previously reported (27), highest levels of albumin mRNA were found in the periportal zone (acinar zone 1) with diminished levels peripherally (acinar zone 3). In contrast, the TNF α mice before weight loss had a marked decrease in albumin mRNA levels throughout the hepatic lobule, with loss of the gradient between acinar zones 1 and 3 (Fig. 4 B). Minimal background in situ hybridization was observed when a ³⁵S-labeled sense albumin RNA probe was used as a control, therefore, validating the specificity of the antisense probe (Fig. 4, C and D).

Decreased albumin mRNA levels may reflect either decreased albumin gene transcription or increased albumin mRNA degradation. Transcription runoff assays were performed in order to measure albumin gene expression in hepatic nuclei obtained from TNF α and CHO mice 16 d postinoculation. Albumin gene transcription was decreased by 90% in TNF α murine livers in a representative runoff assay (Fig. 5). This inhibition of albumin gene transcription apparently accounts for the decreased albumin mRNA in the TNF α murine livers. The transcriptional rates of the β -actin gene were unchanged (Fig. 5) suggesting a selective effect of TNF α on albumin gene expression.

Discussion

In this study we use a novel model of cachexia to maintain chronically elevated serum levels of TNF α in mice. The results demonstrate that elevated serum levels of TNF α lead to decreased albumin gene transcription (Fig. 5), decreased steady state levels of albumin mRNA throughout the hepatic lobule (Figs. 3 and 4), decreased albumin production (Fig. 2), and decreased serum albumin levels (Table II). The inhibition of

Figure 2. Immunohistochemical detection of albumin in liver sections of CHO and TNF α mice. 34 d postinoculation, frozen liver sections of CHO mice (*A*) and TNF α mice (*B*) were incubated with affinity purified antibodies to murine albumin, as described in Methods. $\times 100$ (*A* and *B*).

Figure 3. Northern blot analysis of albumin mRNA levels of livers from CHO and TNF α mice. 2 μ g of poly A⁺ liver RNA from TNF α mice after the onset of weight loss (34 d, *A*) before the onset of weight loss (16 d, *B*), and from the respective CHO-control mice (*A* and *B*) were electrophoresed, transferred, and hybridized to radiolabeled cDNAs for murine albumin, β -actin, complement C3, or α -tubulin.

albumin gene transcription occurs before the onset of weight loss in this animal model.

Hypoalbuminemia has been examined in two other experimental conditions: acute fasting and acute inflammation. In fasted rats the decreased albumin synthesis results from a decrease in albumin mRNA and the amount of albumin mRNA bound to polyribosomes (25, 26). Upon refeeding, the albumin mRNA reverts to its normal distribution (28). A similar decrease in albumin synthesis and disaggregation of polyribosomes is found in perfused livers from fasted animals, both of which were reversed by the addition of ornithine or spermine to the perfusate (29). Although the disaggregation of liver polyribosomes has not been assessed in cachexia, the marked inhibition of albumin gene transcription appears to be the predominant mechanism for the decreased albumin synthesis demonstrated in this experimental model.

Acute inflammation induced by inoculation with either turpentine (2, 30) or bacterial lipopolysaccharide (31) causes a stimulation in the synthesis of acute phase reactants with a concomitant decrease in albumin mRNA levels. This decrease

Figure 4. Distribution of albumin mRNA detected by in situ hybridization in the liver sections of CHO and TNF α mice. Before the onset of weight loss (16 d postinoculation) liver sections of CHO mice (*A* and *C*) and TNF α mice (*B* and *D*) were hybridized with ³⁵S-labeled albumin antisense RNA (*A* and *B*) or with ³⁵S-labeled albumin sense RNA (*C* and *D*). $\times 200$.

in steady state mRNA levels is reproduced in vivo by the inoculation of monocytic products (2). In agreement with the in vivo finding, the monokine IL-1 decreases albumin synthesis and mRNA levels in primary murine hepatocyte cultures (28, 32). $\text{TNF}\alpha$ might have a direct role in albumin gene expression, since $\text{TNF}\alpha$ decreased albumin mRNA and albumin synthesis in human hepatoma cell lines (33, 34). However, in primary rat hepatocyte cultures, $\text{TNF}\alpha$ decreased albumin synthesis only by 10–30% (35). Thus, the effects of $\text{TNF}\alpha$ on albumin synthesis by normal hepatocytes in vitro are inconclusive. To our knowledge, no evaluation of the effects of $\text{TNF}\alpha$ on albumin gene expression has been performed previously.

Besides decreasing albumin synthesis in vivo, the acute phase response increases the synthesis of species-specific acute phase reactants, which include serum amyloid A, gamma fibrinogen, several complement proteins and $\alpha 2$ macroglobulin in the mouse (31, 32). Although $\text{TNF}\alpha$ is capable of inducing a limited subset of acute phase reactants in vitro (32–35), the serum levels of these proteins are not elevated in cachexia-as-

sociated chronic diseases. In the $\text{TNF}\alpha$ -secreting cachectic mice, the hepatic steady state mRNA levels of $\alpha 2$ macroglobulin, gamma-fibrinogen, and C3 are not increased. Therefore, the $\text{TNF}\alpha$ mice represent a good model for the cachexia of chronic disease.

We (23) and others (24, 25) have previously demonstrated that weight loss induced by fasting is associated with decreased albumin synthesis and mRNA levels in rats. Therefore, the decreased albumin synthesis and mRNA levels in the cachectic $\text{TNF}\alpha$ mice could be related to either weight loss or other factors including $\text{TNF}\alpha$. To eliminate the confounding effect of weight loss on albumin gene expression, we studied $\text{TNF}\alpha$ mice before the onset of weight loss. $\text{TNF}\alpha$ markedly inhibited albumin gene transcription despite the absence of weight loss. These findings indicate that $\text{TNF}\alpha$ may be responsible, at least in part, for the inhibition of albumin synthesis that is characteristic of cachexia-associated infection, inflammation, and cancer, all of which manifest elevated $\text{TNF}\alpha$ levels. To the extent that our experimental conditions reflect human cachexia, our results provide an alternative hypothesis to the

Figure 4 (Continued)

Figure 5. Run-off transcriptional assay from nuclei isolated from the livers of CHO and TNF α mice at 16 d postinoculation before the onset of weight loss. Purified radiolabeled nascent RNA (2×10^7 cpm) from hepatic nuclei were hybridized to 0.5 μ g of each cDNA insert immobilized on

nitrocellulose filters. The amount of hybridization was quantitated by liquid scintillation spectroscopy for individual cDNAs.

concept that malnutrition and weight loss are the major factors responsible for the depressed albumin synthesis in cachectic patients.

In vivo, TNF α might be acting directly by binding to its hepatocyte receptor or indirectly by stimulating the release of a second agonist, such as IL-1 or IL-6 (37, 38). IL-1 is also able to inhibit albumin synthesis in vitro (35). However, neither IL-1 nor IL-6 levels have been evaluated in cachexia. The interactions of these polypeptides can be specifically evaluated in primary hepatocyte cultures.

If TNF α directly inhibits albumin gene expression, then future studies must identify the intracellular messenger that mediates this response. We have previously shown that TNF α can modulate transcription through the AP-1 binding site by activating protein kinase C and stimulating the synthesis of the transcriptional factors JUN/AP-1 and FOS (39). In other systems, TNF α stimulates transcription in a protein kinase C independent pathway that might involve cyclic AMP (38). Recent studies have demonstrated that TNF α can also stimulate transcription by increasing nuclear factor binding to the NF-KB site (40). Further studies may reveal that additional intracellular pathways are activated by TNF α .

A series of positive and negative regulatory regions in the albumin gene have already been characterized by gene transfer, cell-free transcription, and protein binding assays (21, 41–43). Several DNA-binding proteins interact with the albumin promoter and are required for liver-specific control of albumin gene transcription. TNF α may modify these hepatic DNA-binding proteins, thereby inhibiting albumin gene transcription. This animal model of cachexia provides a unique opportunity to assess whether these transcriptional factors are affected in vivo by TNF α .

TNF α inhibits albumin gene expression independent of weight loss in this experimental model, and TNF α levels are elevated in patients with cachexia-associated diseases. Therefore, some of the metabolic changes including hypoalbuminemia that characterize cachectic patients might reflect the effects of TNF α .

Acknowledgments

We thank Linda Veloz, Michael Filip, and Charles Johnson for their excellent technical assistance, Andrea Arata for the typing of this manuscript, and Braun Brelin for preparing the graphics.

This work was supported by United States Public Health Service Grants DK07202, DK38652, and GM41804, grants from the Veterans Administration, and a University of California at San Diego Academic

Senate research award. D. A. Brenner is a Pew Scholar in the Biomedical Sciences, M. Chojkier is a recipient of a Research Career Development Award, Veterans Administration, and M. Buck and S. Feitelberg were American Liver Foundation Fellows.

References

1. Rothschild, M. A., M. Oratz, and S. S. Schreiber. 1988. Serum albumin. *Hepatology* 8:385–401.
2. Mosage, H. J., J. A. M. Janssen, J. H. Franssen, J. C. M. Hafkenschied, and S. H. Yap. 1987. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. *J. Clin. Invest.* 79:1635–1641.
3. Zern, M. A., S. H. Yap, R. K. Strair, G. A. Kaysen, and D. A. Shafritz. 1984. Effects of chronic renal failure on protein synthesis and albumin messenger ribonucleic acid in rat liver. *J. Clin. Invest.* 73:1167–1174.
4. Beutler, B., and A. Cerami. 1986. Cachectin and tumour necrosis factor as two sides of the same biological coin. *Nature (Lond.)* 320:584–588.
5. Beutler, B., and A. Cerami. 1987. Cachectin: more than a tumor necrosis factor. *N. Engl. J. Med.* 316:379–385.
6. Oliff, A., D. Defeo-Jones, M. Boyer, D. Martinez, D. Kiefer, G. Vuocolo, A. Wolfe, and S. H. Socher. 1987. Tumors secreting human TNF α /cachectin induce cachexia in mice. *Cell* 50:555–563.
7. Tracey, K. J., H. Wei, K. R. Manogue, Y. Fong, D. G. Hesse, H. T. Nguyen, G. C. Kuo, B. Beutler, R. S. Cotran, A. Cerami, and S. F. Lowry. 1988. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. *J. Exp. Med.* 167:1211–1227.
8. Starnes, H. F. Jr., R. S. Warren, M. Jeevanandam, J. L. Gabrilove, W. Larchian, H. F. Oettgen, and M. F. Brennan. 1988. Tumor necrosis factor and the acute metabolic response to tissue injury in man. *J. Clin. Invest.* 82:1321–1325.
9. Balkwill, F., F. Burke, D. Talbot, J. Tavernier, R. Osborne, S. Naylor, H. Durbin, and W. Fiers. 1987. Evidence for tumour necrosis factor/cachectin production in cancer. *Lancet* ii:1229–1232.
10. Lähdevirta, J., C. P. J. Maury, A.-M. Teppo, and H. Repo. 1988. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. *Am. J. Med.* 85:289–291.
11. Armstrong, C. A., J. Klostergaard, and G. A. Granger. 1985. Isolation and initial characterization of tumoricidal monokine(s) from the human monocytic leukemia cell line THP-1. *J. Natl. Cancer Inst.* 74:1–9.
12. Doumas, B. T., W. A. Watson, and H. G. Biggs. 1971. Albumin standards and the measurement of serum albumin with bromocresol green. *Clin. Chim. Acta* 31:87–96.
13. Kioussis, D., F. Eiferman, P. van de Rijn, and S. Tilgham. 1981. The evolution of α fetoprotein and albumin. *J. Biol. Chem.* 256:1960–1967.
14. Cowan, N. J., P. R. Dobner, E. V. Fuchs, and D. W. Cleveland. 1983. Expression of human α -tubulin genes: interspecies conservation of 3' untranslated regions. *Mol. Cell. Biol.* 3:1738–1745.
15. Gehring, M. R., B. R. Shiels, W. Northemann, M. H. L. de Bruijn, C.-C. Kan, A. C. Chain, D. J. Noonan, and G. H. Fey. 1987. Sequence of rat liver α_2 -macroglobulin and acute phase control of its messenger RNA. *J. Biol. Chem.* 262:446–454.
16. Domdey, H., K. Wiebauer, M. Kazmaier, V. Müller, K. Odink, and G. Fey. 1982. Characterization of the mRNA and cloned cDNA specifying the third component of mouse complement. *Proc. Natl. Acad. Sci. USA* 79:7619–7623.
17. Feinberg, A. P., and B. Volgenstein. 1983. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. *Anal. Biochem.* 132:6–13.
18. Brenner, D. A., and M. Chojkier. 1987. Acetaldehyde increases collagen gene transcription in cultured human fibroblasts. *J. Biol. Chem.* 262:17690–17695.

19. Angerer, L. M., M. H. Stoler, and R. C. Angerer. 1987. *In situ* hybridization with RNA probes: an annotated recipe. In *In situ* hybridization: Applications to neurobiology. K. L. Valentino, J. H. Ebbene, and J. D. Barchas, editors. Oxford University Press, New York. 3:42-70.
20. Ingham, P. W., K. R. Howard, and D. Ish-Horowicz. 1985. Transcription pattern of the *Drosophila* segmentation gene hairy. *Nature (Lond.)* 318:439-445.
21. Gorski, K., M. Carneiro, and U. Schibler. 1986. Tissue-specific *in vitro* transcription from the mouse albumin promoter. *Cell* 47:767-776.
22. Groudine, M., M. Peretz, and H. Weintraub. 1981. Transcriptional regulation of hemoglobin switching in chicken embryos. *Mol. Cell. Biol.* 3:281-288.
23. Wang, X.-F., and K. Calame. 1985. The endogenous immunoglobulin heavy chain enhancer can activate tandem V_H promoters separated by a large distance. *Cell* 43:659-665.
24. Chojkier, M., M. Flaherty, B. Peterkofsky, G. H. Majmudar, R. G. Spanheimer, and D. A. Brenner. 1988. Different mechanisms decrease hepatic collagen and albumin production in fasted rats. *Hepatology* 8:1040-1045.
25. Yap, S. H., R. K. Strair, and D. A. Shafritz. 1978. Effect of a short term fast on the distribution of cytoplasmic albumin messenger ribonucleic acid in rat liver. *J. Biol. Chem.* 253:4944-4950.
26. Shafritz, D. A., S. H. Yap, and R. K. Strair. 1979. Regulation of albumin synthesis by rat liver. *Mol. Biol. Rep.* 5:71-78.
27. Evarts, R. P., P. Nagy, E. Marsden, and S. S. Thorgeirsson. 1987. *In situ* hybridization studies on expression of albumin and α -feto-protein during the early stages of neoplastic transformation in rat liver. *Cancer Res.* 47:5469-5475.
28. Yap, S. H., R. K. Strair, and S. A. Shafritz. 1978. Identification of albumin mRNPs in the liver. *Biochem. Biophys. Res. Commun.* 83:427-433.
29. Oratz, M., M. A. Rothschild, S. S. Schreiber, A. Burks, J. Mongelli, and B. Matarese. 1983. The role of urea cycle and polyamines in albumin synthesis. *Hepatology* 3:567-571.
30. Princen, J. M. G., W. Niewenhuizen, G. P. B. M. Mol-Backx, and S. H. Yap. 1981. Direct evidence of transcriptional control of fibrinogen and albumin synthesis in rat liver during the acute phase response. *Biochem. Biophys. Res. Commun.* 102:717-723.
31. Ciliberto, G., R. Arcone, E. F. Wagner, and U. Rther. 1987. Inducible and tissue-specific expression of human C-reactive protein in transgenic mice. *EMBO (Eur. Mol. Biol. Organ.) J.* 6:4017-4022.
32. Ramadori, G., J. D. Sipe, C. A. Dinarello, S. B. Mizel, and H. R. Colten. 1985. Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. *J. Exp. Med.* 162:930-942.
33. Darlington, G. J., D. R. Wilson, and L. B. Lachman. 1986. Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells *in vitro*. *J. Cell Biol.* 103:787-793.
34. Perlmutter, D. H., C. A. Dinarello, P. I. Punsal, and H. R. Colten. 1986. Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. *J. Clin. Invest.* 78:1349-1354.
35. Koj, A., A. Kurdowska, D. Magielska-Zero, H. Rokita, J. D. Sipe, J. M. Dayer, S. Demczuk, and J. Gauldie. 1987. Limited effects of recombinant human and murine interleukin 1 and tumour necrosis factor on production of acute phase proteins by cultured rat hepatocytes. *Biochem. Int.* 14:553-560.
36. Andus, T., P. C. Heinrich, J. Bauer, T.-A. Tran-Thi, K. Decker, D. Mnnel, and H. Northoff. 1987. Discrimination of hepatocyte-stimulating activity from human recombinant tumor necrosis factor α . *Eur. J. Immunol.* 17:1193-1197.
37. Kohase, M., L. T. May, I. Tamm, J. Vilcek, and P. B. Sehgal. 1987. A cytokine network in human diploid fibroblasts: interactions of β -interferons, tumor necrosis factor, platelet-derived growth factor, interleukin-1. *Mol. Cell. Biol.* 7:273-280.
38. Zhang, Y., J.-X. Lin, and J. Vilcek. 1988. Synthesis of interleukin 6 (interferon- β_2 /B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. *J. Biol. Chem.* 263:6177-6182.
39. Brenner, D. A., M. O'Hara, P. Angel, M. Chojkier, and M. Karin. 1989. Prolonged activation of *jun* and collagenase genes by tumour necrosis factor- α . *Nature (Lond.)* 337:661-663.
40. Duh, E. J., W. J. Maury, T. M. Folks, A. S. Fauci, and A. B. Rabson. 1989. Tumor necrosis factor α activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-KB sites in the long terminal repeat. *Proc. Natl. Acad. Sci. USA.* 86:5974-5978.
41. Babiss, L. E., R. S. Herbst, A. L. Bennett, and J. E. Darnell, Jr. 1987. Factors that interact with the rat albumin promoter are present both in hepatocytes and other cell types. *Genes & Dev.* 1:256-267.
42. Pinkert, C. A., D. M. Ornitz, R. L. Brinster, and R. D. Palmiter. 1987. An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. *Genes & Dev.* 1:268-276.
43. Lichtsteiner, S., J. Warin, and U. Schibler. 1987. The interplay of DNA-binding proteins on the promoter of the mouse albumin gene. *Cell* 51:963-973.